Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-IgE antibody for symptomatic systemic mastocytosis
ACTRN12609000886280Phase 4Not yet recruiting
- Sponsor
- Dr Karl Bleasel
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of omalizumab in systemic mastocytosis (SM) and mastocytosis, sponsored by Dr Karl Bleasel. Primary endpoint: Effect of treatment on symptoms of mastocytosis. Planned start Nov 2009; status: not yet recruiting.
02
Drugs
omalizumab
03
Conditions
systemic mastocytosis (SM)mastocytosis
Beyond the preview
Go deeper on ACTRN12609000886280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000886280.